Mark Lovern

650 total citations
21 papers, 493 citations indexed

About

Mark Lovern is a scholar working on Epidemiology, Pharmacology and Infectious Diseases. According to data from OpenAlex, Mark Lovern has authored 21 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 5 papers in Pharmacology and 4 papers in Infectious Diseases. Recurrent topics in Mark Lovern's work include Antibiotics Pharmacokinetics and Efficacy (5 papers), Pneumonia and Respiratory Infections (4 papers) and Antibiotic Resistance in Bacteria (4 papers). Mark Lovern is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (5 papers), Pneumonia and Respiratory Infections (4 papers) and Antibiotic Resistance in Bacteria (4 papers). Mark Lovern collaborates with scholars based in United States, United Kingdom and Belgium. Mark Lovern's co-authors include Todd Riccobene, Timothy J. Carrothers, Paul M. Schlosser, Shampa Das, Armel Stockis, Benoît Lacroix, Lena E. Friberg, Mats O. Karlsson, Maria Laura Sargentini‐Maier and Yuan Xiong and has published in prestigious journals such as Scientific Reports, CHEST Journal and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Mark Lovern

20 papers receiving 474 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Lovern United States 12 137 124 113 57 54 21 493
Maobai Liu China 17 97 0.7× 96 0.8× 120 1.1× 125 2.2× 23 0.4× 87 815
Bindu Murthy United States 14 141 1.0× 61 0.5× 58 0.5× 64 1.1× 119 2.2× 41 672
Kersti Oselin Estonia 15 175 1.3× 102 0.8× 39 0.3× 70 1.2× 27 0.5× 41 721
Nynke G L Jager Netherlands 15 266 1.9× 91 0.7× 57 0.5× 123 2.2× 20 0.4× 38 719
Robin Michelet Germany 13 187 1.4× 94 0.8× 42 0.4× 164 2.9× 41 0.8× 65 703
Estelle Marrer Switzerland 11 94 0.7× 96 0.8× 64 0.6× 236 4.1× 18 0.3× 13 885
Tadanori Sasaki Japan 12 52 0.4× 67 0.5× 25 0.2× 106 1.9× 17 0.3× 62 566
Luis Jáuregui United States 14 179 1.3× 188 1.5× 59 0.5× 59 1.0× 9 0.2× 69 654
Kunihiko Morita Japan 17 267 1.9× 134 1.1× 75 0.7× 83 1.5× 32 0.6× 78 843
Takahiro Shibayama Japan 12 120 0.9× 56 0.5× 70 0.6× 104 1.8× 6 0.1× 37 437

Countries citing papers authored by Mark Lovern

Since Specialization
Citations

This map shows the geographic impact of Mark Lovern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lovern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lovern more than expected).

Fields of papers citing papers by Mark Lovern

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lovern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lovern. The network helps show where Mark Lovern may publish in the future.

Co-authorship network of co-authors of Mark Lovern

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lovern. A scholar is included among the top collaborators of Mark Lovern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lovern. Mark Lovern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gong, Xiaohua, Ayman Akil, Tao Ji, et al.. (2023). Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1784–1794. 1 indexed citations
2.
Shen, Jun, et al.. (2022). 34507 Deucravacitinib exposure-response analyses in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology. 87(3). AB41–AB41. 1 indexed citations
3.
Han, Kelong, Mark Baker, Mark Lovern, et al.. (2022). Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects. British Journal of Clinical Pharmacology. 88(10). 4607–4622. 32 indexed citations
4.
Murray, Jackelyn, Robert J. Hogan, David E. Martin, et al.. (2021). Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro. Scientific Reports. 11(1). 18085–18085. 28 indexed citations
5.
Yi, B. Alexander, Debra Freedholm, Xiaohui Wang, et al.. (2021). Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. Journal of Thrombosis and Haemostasis. 20(2). 307–315. 72 indexed citations
6.
McFadyen, Lynn, Kenny J. Watson, Todd Riccobene, et al.. (2021). Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older. Clinical Pharmacology & Therapeutics. 111(3). 635–645. 21 indexed citations
7.
Li, Jianguo, Mark Lovern, Todd Riccobene, et al.. (2020). Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy. 64(4). 27 indexed citations
8.
9.
Li, Jianguo, Mark Lovern, Michelle Green, et al.. (2018). Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clinical and Translational Science. 12(2). 151–163. 77 indexed citations
10.
Lovern, Mark, Suzanne K. Minton, Kashyap Patel, et al.. (2017). Applications of Influenza Viral Kinetic Modeling in Drug Development. Current Pharmacology Reports. 3(5). 294–300. 2 indexed citations
11.
Gheyas, Ferdous, Junghoon Lee, Anne Chain, et al.. (2015). Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar. Journal of Pharmacokinetics and Pharmacodynamics. 42. 1 indexed citations
12.
Wilfret, David, Christian Voitenleitner, Mark Lovern, et al.. (2014). A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects. Clinical Pharmacology in Drug Development. 3(6). 439–448. 2 indexed citations
13.
Shelton, Mark, et al.. (2011). Zanamivir Pharmacokinetics and Pulmonary Penetration into Epithelial Lining Fluid following Intravenous or Oral Inhaled Administration to Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy. 55(11). 5178–5184. 27 indexed citations
14.
Lovern, Mark, Mark Underwood, Garrett Nichols, & Ivy Song. (2010). PK/PD modeling supports the dose-escalation decision in VIKING. Journal of the International AIDS Society. 13. P182–P182.
15.
Lacroix, Benoît, Mark Lovern, Armel Stockis, et al.. (2009). A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis. Clinical Pharmacology & Therapeutics. 86(4). 387–395. 50 indexed citations
16.
Lovern, Mark, et al.. (2009). Population pharmacokinetic and pharmacodynamic analysis in allergic diseases. Drug Metabolism Reviews. 41(3). 475–485. 4 indexed citations
17.
Brache, Vivian, Frank Álvarez, Aníbal Faúndes, et al.. (2002). Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women. Human Reproduction. 17(6). 1472–1476. 45 indexed citations
18.
Lovern, Mark, et al.. (2001). A Review of Quantitative Studies of Benzene Metabolism. Critical Reviews in Toxicology. 31(3). 285–311. 32 indexed citations
19.
Lovern, Mark. (1999). Use of a mathematical model of rodent in vitro benzene metabolism to predict human in vitro metabolism data. Carcinogenesis. 20(8). 1511–1520. 18 indexed citations
20.
Lovern, Mark. (1997). Identification of benzene oxide as a product of benzene metabolism by mouse, rat, and human liver microsomes. Carcinogenesis. 18(9). 1695–1700. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maobai Liu Breakdown of academic impact, for papers by Bindu Murthy Breakdown of academic impact, for papers by Kersti Oselin Breakdown of academic impact, for papers by Nynke G L Jager Breakdown of academic impact, for papers by Robin Michelet Breakdown of academic impact, for papers by Estelle Marrer Breakdown of academic impact, for papers by Tadanori Sasaki Breakdown of academic impact, for papers by Luis Jáuregui Breakdown of academic impact, for papers by Kunihiko Morita Breakdown of academic impact, for papers by Takahiro Shibayama
Rankless by CCL
2026